| Authors: |
Noorduyn SG; Global Real-World Evidence, GSK, 100 Milverton Drive, Suite 800, Mississauga, ON, L5R 4H1, Canada. stephen.g.noorduyn@gsk.com.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. stephen.g.noorduyn@gsk.com., Oppenheimer JJ; University of Medicine and Dentistry of New Jersey-Rutgers, Newark, NJ, USA., Moore AC; Global Medical Affairs, General Medicines, GSK, London, UK., Nagase H; Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan., Crawford J; Development Biostatistics, GSK, London, UK., Poddar A; RII: Respiratory, GSK, Bangalore, India., Boon V; Global Clinical Operations, GSK, Collegeville, PA, USA., Brown N; Clinical Sciences, Respiratory, GSK, London, UK., Slade D; Respiratory Clinical Research Unit, GSK, Collegeville, PA, USA., Garcia G; Respiratory Research Center, La Plata, Argentina., Baptist AP; Division of Allergy and Immunology, Henry Ford Health, Detroit, MI, USA., Penz E; Division of Respirology and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.; Respiratory Research Center, University of Saskatchewan, Saskatoon, SK, Canada. |
